Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.55 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL5999497 | 0.85 | CFTR (0.61) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10446411 | 0.84 | CFTR (0.58) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL5998629 | 0.84 | TBXAS1 (0.52) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL5999985 | 0.83 | KCNA5 (0.46) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17071838 | 0.83 | CFTR (0.63) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14283944 | 0.83 | CFTR (0.63) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2601115 | 0.83 | CFTR (0.63) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17069338 | 0.83 | CFTR (0.63) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5023967 | 0.81 | TBXAS1 (0.54) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6581164 | 0.81 | TBXAS1 (0.53) | TBXAS1CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | TBXAS1 2230/4885CFTR 4219/4885SLC6A2 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.